Scholarly Index
Annaliesa S. Anderson
Pfizer (United States); 11,386 total citations; 223 total publications; best world rank #67
Pfizer (United States)
11,386Total citations
223Total publications
52H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Pneumonia and Respiratory Infections | Lifetime | 932 | US 350 | 97.16 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 772 | US 308 | 96.88 |
| Bacterial Infections and Vaccines | Lifetime | 658 | US 246 | 95.65 |
| Neonatal and Maternal Infections | Lifetime | 970 | US 361 | 88.76 |
| Pneumonia and Respiratory Infections | 2021-2025 | 133 | US 38 | 96.52 |
| Neonatal and Maternal Infections | 2021-2025 | 67 | US 18 | 92.58 |
| Streptococcal Infections and Treatments | 2021-2025 | 183 | US 46 | 91.22 |
| Bacterial Infections and Vaccines | 2021-2025 | 224 | US 52 | 88.20 |
| Viral gastroenteritis research and epidemiology | 2021-2025 | 972 | US 301 | 88.23 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 720 | US 210 | 81.75 |